SEC Filing – Corcept Therapeutics, Incorporated

View:

SEC FORM 3 SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

WILSON JAMES N

(Last)

(First)

(Middle)

C/O CORCEPT THERAPEUTICS INCORPORATED

275 MIDDLEFIELD ROAD

(Street)

MENLO PARK

94025

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
04/14/2004

3. Issuer Name and Ticker or Trading Symbol
CORCEPT THERAPEUTICS INC [ CORT ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	606,060	I	by James and Pamela Wilson Family Partners⁽⁶⁾
Common Stock	1,164,879	I	by James N. Wilson and Pamela D. Wilson Trust⁽⁶⁾

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Series A Preferred Stock	⁽¹⁾	⁽⁴⁾	Common Stock	277,779	⁽²⁾	I	by James N. Wilson and Pamela D. Wilson Trust⁽⁶⁾
Series B Preferred Stock	⁽¹⁾	⁽⁴⁾	Common Stock	120,003	⁽²⁾	I	by James N. Wilson and Pamela D. Wilson Trust⁽⁶⁾
Series BB Preferred Stock	⁽¹⁾	⁽⁴⁾	Common Stock	25,433	⁽³⁾	I	James N. Wilson and Pamela D Wison Trust⁽⁶⁾
Series A Preferred Stock	⁽¹⁾	⁽⁴⁾	Common Stock	13,887	⁽²⁾	I	David Wilson⁽⁵⁾
Series B Preferred Stock	⁽¹⁾	⁽⁴⁾	Common Stock	4,998	⁽²⁾	I	David Wilson⁽⁵⁾
Series BB Preferred Stock	⁽¹⁾	⁽⁴⁾	Common Stock	6,358	⁽³⁾	I	David Wilson⁽⁵⁾
Series A Preferred Stock	⁽¹⁾	⁽⁴⁾	Common Stock	85,893	⁽²⁾	I	Ed West and Beth Ann Wilson West⁽⁵⁾
Series B Preferred Stock	⁽¹⁾	⁽⁴⁾	Common Stock	9,999	⁽²⁾	I	Ed West and Beth Ann Wilson West⁽⁵⁾
Series C Preferred Stock	⁽¹⁾	⁽⁴⁾	Common Stock	8,954	⁽³⁾	I	Ed West and Beth Ann Wilson West⁽⁵⁾
Series A Preferred Stock	⁽¹⁾	⁽⁴⁾	Common Stock	27,777	⁽²⁾	I	Arterburn/Watters Trust⁽⁵⁾
Series B Preferred Stock	⁽¹⁾	⁽⁴⁾	Common Stock	9,999	⁽²⁾	I	Arterburn/Watters Trust⁽⁵⁾
Series BB Preferred Stock	⁽¹⁾	⁽⁴⁾	Common Stock	6,358	⁽³⁾	I	Wilson Family Trust⁽⁵⁾

Explanation of Responses:

1. Immediately

2. Each share is convertible without consideration into three (3) shares of Common Stock.

3. Each share is convertible without consideration into one (1) share of Common Stock.

4. Not applicable

5. The reporting person has voting control of the shares and disclaims beneficial ownership of them.

6. The reporting person disclaims beneficial ownership to the shares, except to the extent of his pecuniary interest therin.

	/s/ Fred Kurland, CFO of Corcept Therapeutics Incorporated attorney-in-fact	04/14/2004
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

rrd30239_35043.html



POWER OF ATTORNEY FOR SECTION 16 REPORTING
The undersigned hereby appoints Joseph K. Belanoff, in his capacity as
Chief Executive Officer of Corcept Therapeutics Incorporated (the "Company"),
Andrew Galligan, in his capacity as Chief Financial Officer of the Company, and
either of them with full power of substitution or their respective successors in any
such offices, as the attorney-in-fact of the undersigned to execute and file with the
Securities and Exchange Commission ("SEC") and any other authority required by
the rules and regulations of the SEC or any market or exchange on which shares of
the Company are traded and to submit to the Company, in the place and stead of
the undersigned, SEC Forms 3, 4 and 5 and any successor reporting forms
required by the SEC in connection with purchases and sales of securities of the
Company and any other transactions in securities of the Company reportable on
any such form.  This Power of Attorney shall be effective until revoked by a
written instrument executed by the undersigned and delivered to the Company at
its headquarters to the attention of the Chief Financial Officer.
Dated:  January 29, 2002

/s/ James N. Wilson
Name:  James N. Wilson